Martingale Asset Management L P Allogene Therapeutics, Inc. Transaction History

Martingale Asset Management L P

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$3.17 - $5.96 $10,461 - $19,668	3,300 Added 13.62%	27,526 $87,000
Q2 2023 Aug 11, 2023	SELL	$4.53 - $6.74 $22 - $33	-5 Reduced 0.02%	24,226 $120,000
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $8,256 - $13,824	-800 Reduced 3.2%	24,231 $262,000
Q2 2022 Aug 11, 2022	SELL	$6.78 - $12.28 $101 - $184	-15 Reduced 0.06%	25,031 $285,000
Q4 2021 Feb 11, 2022	BUY	$13.13 - $24.52 $38,405 - $71,721	2,925 Added 13.22%	25,046 $373,000
Q3 2021 Nov 12, 2021	BUY	$21.01 - $27.64 $105,050 - $138,200	5,000 Added 29.2%	22,121 $568,000
Q2 2021 Aug 13, 2021	BUY	$23.49 - $35.8 $402,172 - $612,931	17,121 New	17,121 $446,000

174

139M

75.8K

52.8K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $293M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.